Trial intelligence / Profile preview

Epclusa after HCV-positive donor solid organ transplantation in HCV-negative adult recipients

2018-003640-23Phase 2Terminated

Sponsor
UPMC ISMETT
Start
Jan 2021
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of velpatasvir in hepatitis C virus infection, sponsored by UPMC ISMETT. Primary endpoint: Absence of HCV infection at 12 weeks after treatment completion. Started Jan 2021; status: terminated.

02

Drugs

velpatasvir
03

Conditions

hepatitis C virus infection

Beyond the preview

Go deeper on 2018-003640-23.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2018-003640-23.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call